A phase III randomized-controlled, single-blind trial to improve quality of life with stereotactic body radiotherapy for patients with painful bone metastases (ROBOMET) by Mercier, Carole et al.
STUDY PROTOCOL Open Access
A phase III randomized-controlled, single-
blind trial to improve quality of life with
stereotactic body radiotherapy for patients
with painful bone metastases (ROBOMET)
Carole Mercier1,2* , Piet Dirix1,2, Piet Ost3, Charlotte Billiet1,2, Ines Joye1,2, Peter Vermeulen2,4, Yolande Lievens3 and
Dirk Verellen1,2,5
Abstract
Background: Bone metastases represent an important source of morbidity in cancer patients, mostly due to severe
pain. Radiotherapy is an established symptomatic treatment for painful bone metastases, however, when conventional
techniques are used, the effectiveness is moderate. Stereotactic body radiotherapy (SBRT), delivering very high doses in
a limited number of fractions in a highly conformal manner, could potentially be more effective and less toxic.
Methods: This is a phase III, randomized-controlled, single-blind, multicenter study evaluating the response rate of
antalgic radiotherapy for painful bone metastases and the acute toxicity associated with this treatment. A total of 126
patients will be randomly assigned to receive either the standard schedule of a single fraction of 8.0 Gy delivered through
three-dimensional conformal radiotherapy or a single fraction of 20.0 Gy delivered through SBRT. Primary endpoint is pain
response at the treated site at 1 month after radiotherapy. Secondary endpoints are pain flare at 24–48-72 h after
radiotherapy, duration of pain response, re-irradiation need, acute toxicity, late toxicity, quality of life and subsequent
serious skeletal events. In a supplementary analysis, patient-compliance for a paper-and-pencil questionnaire will be
compared with an electronic mode.
Discussion: If a dose-escalated approach within the context of single fraction stereotactic body radiotherapy could
improve the pain response to radiotherapy and minimize acute toxicity, this would have an immediate impact on the
quality of life for a large number of patients with advanced cancer. Potential disadvantages of this technique include
increased pain flare or a higher incidence of radiation-induced fractures.
Trial registration: The Ethics committee of the GZA Hospitals (B099201732915) approved this study on September 4th
2018. Trial registered on Clinicaltrials.gov (NCT03831243) on February 5th 2019.
Keywords: Stereotactic body radiotherapy, Bone metastases, Spinal metastases, Pain
Background
Regrettably, a large proportion of cancer patients will
ultimately develop systemic disease. Bone metastases are
a common manifestation of distant relapse from many
types of solid tumors, especially those arising in the lung,
breast and prostate. They represent an important source
of morbidity in these patients, mostly due to severe pain.
Furthermore, they can cause hypercalcemia, pathologic
fractures and spinal cord compression, all of which can
significantly compromise quality of life. The goals of
palliative radiotherapy of bone metastases are pain relief,
preservation of function, and maintenance of skeletal
integrity. Radiotherapy is an established symptomatic
treatment for painful bone metastases. A common and
convenient schedule uses a single dose of 8 Gy [1].
Several other fractionation schedules, using moderate
dose escalation (5 × 4.0 Gy or 10-13 × 3.0 Gy), have been
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investigated. However, so far, none has demonstrated
superiority to a single 8 Gy fraction [2]. A large meta-ana-
lysis by Rich et al. showed overall response rates of 61%
versus 62% for single fraction and multiple fraction regi-
mens [3]. Complete responses were seen in 23% versus
24% of patients. A drawback of single 8 Gy fraction
treatment is a consistently higher retreatment rate (20%
versus 8% in the meta-analysis). Retreatment gives moder-
ate pain relief (overall pain response rates of 45–58%)
regardless of prior response to palliative radiotherapy [4].
Palliative radiation therapy for bone metastases is
usually performed using conventional or at most
3D-conformal radiotherapy (3D-CRT), rather than
more advanced techniques such as intensity-modulated
radiotherapy (IMRT). As a result, these palliative
patients can sometimes suffer from rather pronounced
acute toxicities, often during the last months of their
lives. Stereotactic body radiotherapy (SBRT) is a recent
state-of-the-art form of radiotherapy, typically deliver-
ing very high doses (> 6.0 Gy per fraction) in a limited
number of fractions (1–5) in a highly conformal
manner. This technique is safe due to corresponding
improvements in image-guided radiotherapy (IGRT),
allowing to continuously monitor the treatment as it is
being delivered [5]. SBRT is able to deliver significantly
higher biologically equivalent doses (BED) as compared
to conventional radiation with improved sparing of
surrounding normal tissues. It has consistently demon-
strated local control rates of around 90%, even in
“radioresistant” tumors [6]. Most studies on SBRT for
bone metastases to date focused on so-called “oligome-
tastatic” patients, with only a limited number of (usu-
ally asymptomatic) metastases, assuming that ablation
of these lesions could result in improved disease-free
and perhaps even overall survival [7]. While this is
certainly a worth-wile approach, it seems reasonable to
also use this technique for palliative patients suffering
from painful bone metastases.
The highly conformal delivery of SBRT will hopefully
result in an improved acute toxicity profile, based on the
experiences captured in patient-reported rather than
physician-reported measures. The concept of quality of
life (QoL) is subjective; however, in many cancer
cohorts, specific tools or patient-reported outcome mea-
sures (PROMs) have been developed and validated [8].
These questionnaires assess common issues that affect
patients after diagnosis and treatment, and generate
scores that reflect the impact on perceptions of health-
related quality of life (HRQoL). A secondary aim of this
study is to compare hand-written “paper” PROMs to
electronic, “paper-less” PROMs.
Moreover, it is now possible to deliver escalated doses
to the metastases. We propose a single fraction (avoiding
the complexity of multiple fractions) of 20.0 Gy, which
has a vastly superior BED compared to the previous
(multiple fraction) dose-escalation attempts. It is to be
assumed that with these truly “ablative” doses, not only
a higher response rate can be achieved but also longer
duration of pain control and less re-irradiation need.
Perhaps this increased efficacy will compensate the
higher treatment cost of SBRT, through less re-treat-
ment and less symptomatic skeletal events (SSEs, con-
sisting of symptomatic pathologic fractures, radiation or
surgery to bone, and spinal cord compression).
Methods/design
Study design
This is a phase III, randomized-controlled, single-blind,
multicenter study comparing the standard schedule for
antalgic radiotherapy of a single fraction of 8.0 Gy deliv-
ered through 3D-CRT to a single fraction of 20.0 Gy
delivered through SBRT (Fig. 1). The primary aim of this
trial is to double the complete response rate. Secondary
aims are to compare pain flare, duration of pain
response, acute and late toxicity, HRQoL through
PROMs, re-irradiation need and subsequent SSE.
All subjects will be randomly assigned in a 1:1 ratio to
receive either a single fraction of 8.0 Gy to the painful
bone metastasis through 3D-CRT (control arm) or a
single fraction of 20.0 Gy to the painful bone metastasis
Fig. 1 Study schema. Subjects who meet eligibility criteria and qualify for enrolment will be randomized as demonstrated
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through SBRT (experimental arm). A block randomization
with a block size of four will be performed by using an
electronic randomization tool (Dyco Capture, DigiDyco).
This study has been approved by the Ethics Commit-
tee of GZA Hospitals and all collaborating institutions.
All patients must provide written informed consent
before enrolment. Monitoring will be carried out in
this trial.
Study objectives
Primary endpoint
Primary endpoint of this study is pain response at the
treated index site at 1 month after RT, as defined ac-
cording to the International Bone Metastases Consensus
Endpoints for Clinical Trials (Table 1) [9].
Secondary endpoints
Secondary endpoints include pain flare at 24–48-72 h
after radiotherapy, the duration of pain response, re-ir-
radiation need, toxicity, HRQoL and subsequent SSE.
Pain flare at 24–48-72 h after radiotherapy is defined as
pain progression according to the consensus statement
[9]. Duration of pain response starts at response until
pain progression. Toxicity will be measured with the
Common Terminology Criteria for Adverse Events
(CTCAE) version 5.0 at 1 month after RT and three-
monthly during the first year after treatment. HRQoL is
measured by the EORTC QLQ-C30 general question-
naire and the bone metastasis-specific module, the
EORTC QLQ-BM22 [10]. Patients fill out these
questionnaires before the start of RT (baseline), 1 month
after RT (primary endpoint) and three-monthly during
the first year after treatment (follow-up). Subsequent
SSE is defined as symptomatic pathologic fractures, radi-
ation or surgery to bone, and spinal cord compression.
Eligibility criteria
Eligible patients are patients with a pain score ≥ 2 on a
scale from 0 to 10 (measured as the worst pain for the
previous 3 days at the index site), with radiological or
(bone) scintigraphic evidence of bone metastasis at the
site of pain and no more than 3 painful lesions needing
treatment. If analgic dosing adjustment is done less than
1 week before initiation of irradiation, a run-in period is
recommended to minimize the risk that the analgesic ef-
fects will confound the measurement of the RT effects.
Patients should have a life expectancy estimated at > 3
months. Per lesion, no more than 3 consecutive spine
segments should be involved, with one unaffected verte-
bral body above and below. Bone metastasis in previ-
ously irradiated sites, or originating from myeloma, or
complicated bone metastasis, i.e. impending and/or
existing pathological fracture, spinal cord compression
or cauda equina compression [11], should be excluded.
Trial treatments
For patients in the standard arm, the current standard
treatment will be prescribed, i.e. a single fraction dose of
8.0 Gy to the metastasis with a planning target volume
(PTV) margin for set-up and positioning uncertainties of
1 cm. This can be performed at any linear accelerator.
In the experimental arm, treatment will be delivered
within the framework of SBRT. A single fraction dose of
20.0 Gy will be delivered to the metastasis using a PTV mar-
gin of 3–5mm based on high-precision IGRT. Therefore,
only linear accelerators with the European Organization for
Radiotherapy & Oncology advisory committee on radiation
oncology practice (ESTRO-ACROP) specifications for
SBRT can be accepted [12]. A risk-adapted approach will be
applied, aiming for the highest possible dose no less than
16Gy, while respecting the tolerances of critical organs at
risk (e.g. spinal cord, cauda equina, brainstem etc.).
Radiotherapy details
Simulation and immobilization
Patient immobilization and CT simulation will be done
similarly as described in a previous published study
protocol from our research group on SBRT for bone
metastases [13].
Target contouring
The gross tumor volume (GTV) will be delineated as vi-
sualized on CT. No clinical target volume (CTV) will be
delineated in the experimental arm. In the standard arm
standard CTV margins (e.g. incorporating the entire
vertebra) are allowed. A planning target volume (PTV)
Table 1 Response rate to radiotherapy according to the international consensus [9]
Complete response Pain score of 0 at the treated site and stable or reduced analgesics in daily oral morphine equivalent
(OMED).
Partial response Pain reduction of 2 or more at the treated site on a scale of 0 to 10 scale without analgesic increase,
or analgesic reduction of 25% or more from baseline without an increase in pain.
Pain progression Increase in pain score of 2 or more above baseline at the treated site with stable OMED, or an
increase of 25% or more in OMED compared with baseline with the pain score stable or 1 point
above baseline
Indeterminate response Any response that is not captured by the complete response, partial response, or pain progression
definitions
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will be created, allowing for daily set-up variance and
organ motion. In the standard arm, PTV margins of 1
cm are common, in the experimental (SBRT) arm, PTV
margins are 3 to 5 mm.
Organs at risk
The organs at risk (OARs) depend on the localization of
the metastases. At least all OARs for which dose
constraints are described in the report of the American
Association of Physicists in Medicine (AAPM) task
group 101 [14], lying within the scanned range on the
planning CT scan, should be delineated. For spinal
lesions, MRI is recommended for spinal cord delinea-
tion. A Planning Organ at Risk Volume (PRV) expansion
of 2-5 mm will be added to the spinal cord, oesophagus,
mediastinum, liver, heart and kidney for setup uncer-
tainty or organ motion. If no MRI is used for delineating
the spinal cord, the whole spinal canal should be delin-
eated as PRV. All dose constraints apply to this PRV and
should not be exceeded. In case of an overlap of the
target with an OAR or PRV, target coverage can be
lowered in order to meet the constraint.
Treatment planning
In the standard arm, 3D-conformal radiotherapy with
basic image-guidance will be used. In the experimental
arm, static or rotational treatment planning will be
applied depending the localization of the metastasis.
Three-dimensional or intensity-modulated coplanar or
non-coplanar beam arrangements will be custom
designed for each case to deliver highly conformal dose
distributions. For high dose-hypofractionated radiother-
apy, typically, ≥ 10 beams of radiation are used with
roughly equal weighting. When static beams are used, a
minimum of 7 beams should be used and non-opposing,
non-coplanar beams are preferable. For arc rotation
techniques, a minimum of 340 degrees (cumulative for
all beams) is warranted.
Dose prescription and constraints
In the standard setting, 95% of the PTV should receive
95% of the prescribed dose while near maximum dose
(Dnear-max) in the PTV should not exceed 107%. In the
experimental arm, treatment will be prescribed to the
periphery of the target, i.e. 80% of the dose should cover
95% of the PTV. In the experimental arm, coverage of
PTV with the prescribed dose (20Gy) should be opti-
mized to reach 90% or more. Coverage of the PTV with
80% of the prescribed dose (16Gy) should at least reach
a minimum of 80% of the PTV with no violations of
treatment planning objectives for OAR. Coverage of <
90% of the PTV with 16Gy is a Variation Acceptable,
and any coverage of < 80% of the PTV with 16Gy is De-
viation Unacceptable. The OAR dose constraints will be
in accordance with the recommendations from the re-
port of the AAPM task group 101 [14]. Maximum PTV
dose up to 140% is allowed but all dose > 105% should
be contained within the GTV. A dose fall-off outside the
PTV extending into normal tissue structures should aim
at 50% of the prescribed dose within 3 cm.
Delivery and verification
In the standard arm, image-guidance will consist of
portal images showing the relevant bony anatomy. For
the experimental arm, treatment will be delivered with
6–18 MV photons of a linear accelerator with ESTRO-
ACROP specifications for SBRT [12]. Image-guidance
will consist of cone-beam CT in combination with 6
degrees of freedom corrections using robotic couch. No
other RT than photon therapy is permitted. The same
position and immobilization/support device(s) as used in
the planning CT scan should be utilized. For the investi-
gational arm, a pre-treatment patient-specific and treat-
ment verification quality assurance (QA) program based
on transmission dose measurements and cone-beam CT
data will be performed.
Treatment compliance
Radiotherapy dosing and delivery will be assessed by
coverage and dose on target volumes GTV, CTV (if used)
and PTV and must be captured in the source documents
and the eCRF.
Interventions
The screening procedures will determine subject eligibil-
ity according to inclusion and exclusion criteria. The
following evaluation/assessments will be performed at
the screening visit within 20 days of Day 1 (Table 2):
– Obtain informed consent
– Record the numeric pain rating scale
– Record the daily oral morphine equivalent (OMED)
and other analgesics
– Record education level and computer experience
– Collect details of disease and concurrent systemic
anticancer treatment
– ECOG performance status
– HRQoL questionnaires (and reason for non-
compliance, if applicable)
– Toxicity (using the most recent version of CTCAE)
At Day 1, randomization and computed tomography
(CT) simulation will be performed.
The following assessments must occur on the day of
radiotherapy treatment (Table 2):
– Record the numeric pain rating scale
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– Record the daily oral morphine equivalent (OMED)
and other analgesics
– Collect RT dosing and delivery details
– ECOG performance status
– HRQoL questionnaires (and reason for non-
compliance, if applicable)
– Toxicity (using the most recent version of CTCAE)
At 24 h, 48 h, 72 h, 1 week (+/− 3 days), 2 weeks (+/− 3
days) and 3 weeks (+/− 3 days) after RT subjects are
asked to rate their pain flare and record concurrent
medications in a pain diary.
The following procedures are to be conducted at pri-
mary endpoint visit (1month after RT) and at each fol-
low-up visit every 3months up to 12months (Table 2):
– Record the numeric pain rating scale
– Record the daily oral morphine equivalent (OMED)
and other analgesics
– Record the need for re-irradiation
– Record the presence of a symptomatic skeletal event
– Determine the pain response
– ECOG performance status
– HRQoL questionnaires (and reason for non-
compliance, if applicable)
– Toxicity (using the most recent version of CTCAE)
Statistical analysis
Sample size calculation
Currently, a complete pain response rate of maximum
25% after a single fraction of 8.0 Gy can be assumed [1–3].
With 116 patients, we can show a statistically significant
increase to 50% in complete pain response (with Type I
error of 0.05 and power of 0.8). Assuming a drop-out rate
of 10%, we need to include 126 patients.
Data analysis
All data will be prospectively collected. Electronic case
report forms will be used. Statistics will be carried out
using the latest version of R.
Safety
Suspected unexpected serious adverse reactions (SUSARs)
that result in death or are life threatening will be reported
to the minister and the competent ethics committee
within 7 days. All other SUSARs will be reported within
15 days following notification. Once a year throughout the
experiment, an annual safety report shall be provided to
the ethics committee, listing all suspected serious adverse
reactions which have occurred over this period, as well as
a report on the safety of the participants. Regarding those
adverse events and serious adverse reactions the Principal
Investigator will take all reasonable measures to protect
subjects at risk following the occurrence of such events.
Compensation for any damages incurred by a study pa-
tient and linked directly or indirectly to the participation
to the study is provided through insurance.
Supplementary analysis
It is well established that patient and clinician symptom
reports are discrepant, with clinicians generally underre-
porting the incidence and magnitude of symptoms
compared with patients [15]. Patient-reported outcome
questionnaires assess topics a patient can report about his
or her own health, including symptoms, physical function-
ing, and mental health. Patients report this information
via questionnaires that have been rigorously developed.
Table 2 Trial flowchart
Screening Treatment Follow-up
Simulation During study Year 1
RT 24–48-72 h weekly 1 m Every 3 m
Informed consent x
Registration of education level, computer experiencea x
Randomization:
1 × 8.0 Gy
1 × 20.0 Gy
x
Numeric Pain Rating Scale x x x x x x
ECOG performance status x x x
OMED + other analgesics x x x x x x
Registration of toxicity x x
Registration of QoLb x x x
Registration of treatment datac x
aEducation level:highest level of education (none, primary school, secundary school or higher education); computer experience: at least once a week access to
computer/e-mail (yes or no)
bQoL according to the EORTC QLQ-C30 & BM22 questionnaires; if form is not completed, reason for non-compliance will be documented in compliance form
cSee Section “Treatment compliance”
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Patient-reported outcome measures (PROM’s) assessed in
cancer randomised controlled trials provide valuable
information on the impact of treatment from the pa-
tient’s perspective. There is even evidence that using
PROM’s in palliative oncological patients improves
overall survival [16].
Yet, shortcomings in PROM’s trial design, methodology
and reporting may limit the interpretation of these data.
When patient responses are utilized as measures of
primary and secondary endpoints, completion of required
assessments is necessary to draw proper conclusions [17].
Efforts should be made to ensure patient-compliance, in
order to provide complete datasets. Non-compliance with
planned questionnaires and missing data can threaten
both internal validity and generalizability. Administrative
failure is one of the most important factors leading to
non-compliance, against others like patients age [18].
Using electronic PROM’s has some important advan-
tages over using paper-and-pencil questionnaires, e.g.
reducing missing data within one assessment, implement-
ing complex skip patterns, eliminating ambiguous data,
reducing effort and error in entering data, registering
response time, and real-time monitoring of PRO, to name
a few. A study evaluating the impact of collecting PROM’s
electronically showed greater benefits for computer-inex-
perienced patients, who were overall older, frailer, and
more symptomatic than computer-experienced patients
[16]. Participants lacking computer experience may have
less-developed health communication skills and thereby
benefit more from a structured program for eliciting
symptoms. A negative effect of collecting PROM’s elec-
tronically is that this reduces physical communication and
interaction between the patient and the medical staff.
As a supplementary analysis, we will compare patient-
compliance for a paper-and-pencil with an electronic
mode. Multiple studies support the between-mode equiva-
lence of paper-and-pencil and electronic PROM’s [19, 20].
For the first 63 patients, a booklet with questionnaires
(pain diary, QLQ-C30, BM22) will be presented at the
visits as defined per protocol. For the last 63 patients, a
smartphone app will be installed on the patient’s own
smart device, in order to complete the same question-
naires electronically. During each visit, the reason for
non-compliance will be documented when a patient does
not complete any part of a questionnaire as required per
protocol.
Logistic regression techniques will be employed to de-
termine if any patient characteristic (e.g. socio-economic
status, educational level, migration background) or
clinical events influenced patient compliance.
Discussion
In this report, we present the rationale and design of the
ROBOMET trial, a randomized study in radiotherapy for
painful bone metastases investigating whether SBRT can
increase the pain response while at the same time limit
the side-effects. It is clear that, although palliative antal-
gic radiotherapy is an established treatment for painful
bone metastases, there is important room for improve-
ment, both regarding efficacy as well as toxicity. Many
costly bone-targeted therapies such as osteoclast inhibi-
tors as well as radiopharmaceutical agents have been
developed, but palliative radiotherapy remains the main-
stay for local treatment and symptom control. It is
therefore to be expected that this patient-directed trial
can improve the quality of life of a great number of
cancer patients worldwide on short term.
One important measure to improve pain response to
radiotherapy would be to escalate the dose delivered to
the tumor. Evidence for this emerges from multiple
prospective studies. Researchers from Ghent University
Hospital randomized (1,1:1) 45 patients with uncompli-
cated painful bone metastases to receive either 8.0 Gy in a
single fraction with conventional radiotherapy (arm A) or
8.0 Gy in a single fraction with dose-painting by numbers
IMRT up to 10.0 Gy (arm B) or 16.0 Gy in a single fraction
with dose-painting by numbers IMRT up to 18.0 Gy (arm
C). The primary endpoint was overall pain response at 1
month. Eight (53%), 12 (80%) and 9 patients (60%) had an
overall response to treatment in arm A, B and C, respect-
ively [21]. In an American single-institute series, 49
patients with 61 separate spinal metastases were treated to
a single fraction of 10.0 to 16.0 Gy [22]. Encouragingly,
complete pain relief was achieved in 46%, partial relief in
18.9%, and stable symptoms in 16.2% of patients. These
data suggest that a single dose-escalated fraction could
result in complete pain response rates of around 50%.
A major advantage of SBRT over 3DCRT is an ex-
pected reduction in dose to the normal tissue, which
presumably will lead to less acute toxicity. Already
numerous case series and multiple prospective trials
have proven that both multi- and single fraction SBRT
schedules for bone metastasis can be delivered with min-
imal toxicity [23–27]. Especially in a palliative setting,
even transient side effects like nausea and diarrhoea are
cumbersome. In this regard, optimisation of palliative
radiation treatment through the use of SBRT is one of
the measures that should be investigated, because quality
of life is for most of these patients of ultimate priority.
On the other side, some reports indicate that high
dose single fraction SBRT is associated with a greater
incidence of pain flare. In prospective studies using
3DCRT for painful bone metastases, the incidence of
pain flare is approximately 40% [28, 29] whereas this in-
cidence ranges between 10 and 68% after SBRT [30–34].
One explanation for this large range is the difference in
fractionation schedules that are used, with a single frac-
tion SBRT potentially leading to more pain flare. Besides
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that, inconsistency in the definitions of pain flare, the
use of retrospective data, administering corticosteroids
in the prevention of pain flare, or physicians rather than
patients reporting pain scores, are other factors making
it difficult to compare between these results.
A potential disadvantage of SBRT could be the higher
rate of vertebral compression fractures (VCF) associated
with this technique. At least in the spine, the use of high
dose single fraction SBRT might be associated with a
higher risk of vertebral compression fractures. In a large
multi-institutional investigation of spine SBRT related
VCF, a dose-complication relationship was observed
based on the dose-per-fraction. A 39% risk of VCF was
observed with high dose single fraction SBRT (≥24 Gy),
23% with a dose per fraction of 20 to 23 Gy, and 11%
when below 20 Gy [35]. In order to identify patients who
are stable, potentially unstable or frankly mechanically
unstable, the Spinal Instability Neoplastic Score (SINS)
was developed [36], which incorporates several of the
significant predictive factors on either uni- or multivari-
ate analysis of trials evaluating VCF after SBRT [37].
Most VCF are observed shortly after SBRT, with a median
time to VCF of 2.6 months according to the systematic re-
view of Faruqi e.a [37]. However, in the calculation of this
median time to VCF, a study with a median of 25months
was treated as outlier and excluded [38]. In order to evalu-
ate the incidence of VCF in our patient cohort, serious
SSE will be evaluated until 1 year after completion of
treatment, which we believe will capture most of the treat-
ment-related VCF’s.
To our knowledge, there are no published randomized
trials comparing conventional to stereotactic radiother-
apy in polymetastatic cancer patients with bone metasta-
ses, but multiple other trials have been initiated to look
at the efficacy and safety of SBRT for painful (spinal)
bone metastases. The American RTOG-0631 trial aimed
to randomize (1:2) 240 patients with localized spinal
metastases between a single conventional RT fraction of
8.0 Gy vs. a single SBRT fraction of 16.0 or 18.0 Gy (with
dose as preferred by the treating physician). Primary
endpoint is complete or partial pain relief at the treated
index site at 3 months. Accrual has recently finished and
results are awaited [39]. This trial is clearly very similar
but focussed exclusively on spinal metastases, where the
dose is limited due to the proximity of the spinal cord.
Another trial is the Dutch VERTICAL trial, aiming to
randomize (1:1) 110 patients with painful bone metasta-
ses to either between a single conventional RT fraction
of 8.0 Gy vs. a single MRI-based SBRT fraction of 18.0
Gy to the visible metastasis and 8.0 Gy to the bony
compartment containing the metastasis. Primary end-
point is complete or partial pain response at 3 months
after radiotherapy. This trial is currently still recruiting
[40]. Recently, the results of a randomized trial of the
Heidelberg University were published. In this trial, 55
patients with painful spinal metastases were treated with
either single fraction SBRT (24Gy) or 3DCRT (30Gy in
10 fractions). The trial demonstrated that single-fraction
SBRT reduced pain levels faster during the 3 months
following RT and led to improved pain scores compared
to 3DCRT.
Currently, the innovations (IMRT, IGRT) that have
fuelled many of the significant advances in curative
radiotherapy are not sufficiently being applied for pallia-
tive indications. This is partly due to limited resources,
since these new techniques take up more time on the
treatment machine and also more extensively occupy
health care providers, both physician, physicist and radi-
ation therapist, compared to conventional radiotherapy.
However, by minimizing subsequent re-irradiation, redu-
cing pain medication and preventing costly SSEs, this
new technique can have a favourable socio-economic
impact. Therefore, randomized evidence supporting the
utility of advanced technologies in the palliative setting
will be needed to convince both the radiation oncology
community as well as the relevant governments and
reimbursement agencies of the need to apply these
innovative techniques to palliative patients.
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